July 26, 2025
At the European Hematology Association (EHA) meeting 2025,Johnson & Johnson presented compelling data from the RedirecTT‑1 Phase II trial evaluating the dual bispecific regimen Talvey (talquetamab) plus Tecvayli (teclistamab) in heavily pretreated, extramedullary relapsed/refractory multiple myeloma (R/R MM) patients. In 90 evaluable patients, the combination produced an overall response rate (ORR) of 78.9%, with over 50% achieving complete response or better. Median duration of response was 13.8 months, and61% of participants remained progression-free and alive at one year. Safety events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), were consistent with established profiles observed in bispecific monotherapies. The significance lies in its efficacy in extramedullary disease—a historically resistant subgroup—and its off-the-shelf administration offering a faster and more accessible alternative to CAR‑T therapies like Carvykti.
Citation: https://www.globenewswire.com/news-release/2025/06/15/3099407/0/en/Investigational-combination-of-first-in-class-bispecific-antibodies-TALVEY-talquetamab-and-TECVAYLI-teclistamab-shows-deep-and-durable-responses-in-heavily-pretreated-multiple-myel.html?utm_source=chatgpt.com
Implication:
The high ORR and durable responses make Talvey + Tecvayli a formidable rival toCarvykti, especially given its simpler logistics and availability. This may recalibrate treatment sequencing toward bispecific combinations for extramedullary and high-risk R/R MM patients.